Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESIGON: Genetic Sensitivity to Chemotherapy Gonadotoxicity in Breast Cancer
NCT03731845Active, not recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2019
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Single-arm trial, sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Assessment of ovarian reserve at 5 years. Started Apr 2019; status: active, not recruiting.
Beyond the preview
Go deeper on NCT03731845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03731845.